AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-30. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
To allocate funds, the NIH must first obtain its budget from Congress. This process begins with institute and center (IC) leaders collaborating with scientists to determine the most important and promising research areas within their fields. IC leaders discuss research areas with NIH management who then develops a budget request for continuing projects, new research proposals, and new initiatives from the Director. The NIH submits its budget request to the Department of Health and Human Services (HHS), and the HHS considers this request as a portion of its budget. Many adjustments and appeals occur between the NIH and HHS before the agency submits NIH's budget request to the Office of Management and Budget (OMB). OMB determines what amounts and research areas are approved for incorporation into the President's final budget. The President then sends the NIH's budget request to Congress in February for the next fiscal year's allocations. The House and Senate Appropriations Subcommittees deliberate and by fall, Congress usually appropriates funding. This process takes approximately 18 months before the NIH can allocate any actual funds. When a government shutdown occurs, the NIH continues to treat people who are already enrolled in clinical trials, but does not start any new clinical trials and does not admit new patients who are not already enrolled in a clinical trial, except for the most critically ill, as determined by the NIH Director.
JDTic is a selective, long-acting ("inactivating") antagonist of the κ-opioid receptor (KOR). JDTic is a 4-phenylpiperidine derivative, distantly related structurally to analgesics such as pethidine and ketobemidone, and more closely to the MOR antagonist alvimopan. In addition, it is structurally distinct from other KOR antagonists such as norbinaltorphimine. JDTic has been used to create crystal structures of KOR [ PDB: 4DJH, 6VI4].
=== Pharmacokinetics === It is possible that MDDMA could be partially demethylated into MDMA. However, based on (R)-MDDMA and (R)-MDMA having very different effects in animals, such conversion appears to be limited.
Classically, the iron in oxyhemoglobin is seen as existing in the iron(II) oxidation state. However, the complex of oxygen with heme iron is diamagnetic, whereas both oxygen and high-spin iron(II) are paramagnetic. Experimental evidence strongly suggests heme iron is in the iron(III) oxidation state in oxyhemoglobin, with the oxygen existing as superoxide anion (O2•−) or in a covalent charge-transfer complex.
Colonel Sanders was a key component of KFC advertising until his death in 1980. Despite his death, Sanders remains a key icon of the company as an "international symbol of hospitality". Early official slogans for the company included "North America's Hospitality Dish" (from 1956) and "We fix Sunday dinner seven nights a week". The "finger lickin' good" slogan was used from 1956 and went on to become one of the best-known slogans of the 20th century. The trademark expired in the US in 2006. The first KFC logo was introduced in 1952 and featured a "Kentucky Fried Chicken" typeface and a logo of the Colonel. In 1962, Dave Thomas took Colonel Sanders' bucket and turned it into a sign that revolved in a circular motion in front of almost every American KFC outlet. Advertising played a key role at KFC after it was sold by Sanders and the company began to advertise on US television with a budget of US$4 million in 1966. In order to fund nationwide advertising campaigns, the Kentucky Fried Chicken Advertising Co-Op was established, giving franchisees 10 votes and the company three when deciding on budgets and campaigns. In 1969, KFC hired its first national advertising agency, Leo Burnett. A notable Burnett campaign in 1972 was the "Get a bucket of chicken, have a barrel of fun" jingle, performed by Barry Manilow. By 1976, KFC was one of the largest advertisers in the US.
Sources: en.wikipedia.org
A stígma (στίγμα) is a mark on the skin. Reported cases of stigmata take various forms. Many show some or all Five Sacred Wounds that were, according to the Bible, inflicted on Jesus during his crucifixion: wounds in the wrists and feet, from nails; and in the side, from a lance. Some stigmatics display wounds to the forehead similar to those caused by the crown of thorns. Stigmata as crown of thorns appearing in the 20th century, e.g. on Marie Rose Ferron, have been repeatedly photographed. Other reported forms include tears of blood or sweating blood, and wounds to the back as from scourging. Many stigmata show recurring bleeding that stops and then starts, at times after receiving Holy Communion; a significant proportion of stigmatics have shown a strong desire to receive Holy Communion frequently. A relatively high percentage of stigmatics also exhibit inedia, claiming to live with minimal (or no) food or water for long periods of time, except for the Holy Eucharist. Some exhibit weight loss, and closer investigation often reveals evidence of fakery. Some stigmatics claim to feel the pain of wounds with no external marks; these are referred to as "invisible stigmata". Some stigmatics' wounds do not appear to clot, and seem to stay fresh and uninfected. The blood from the wounds is said, in some cases, to have a pleasant, perfumed odor, known as the Odour of Sanctity. Individuals who have obtained the stigmata are many times described as ecstatics, overwhelmed with emotions upon receiving the stigmata.
Because protein chains are open, AlphaKnot uses closure procedures before applying knot invariants. Its probabilistic method repeatedly closes the chain using randomly selected points on a large surrounding sphere and assigns the dominant topology obtained from the ensemble of closures. Deterministic alternatives connect the chain termini using prescribed geometries, including a direct closure and a closure constructed using the centre of mass. Knot identification uses the HOMFLY polynomial to distinguish knot types. AlphaKnot recognizes knots with minimal representations containing up to 12 crossings. In large-scale database calculations, structures that exhibit evidence of a nontrivial knot are subsequently analysed to determine the corresponding knot core, the smallest portion of the protein chain required to retain the detected topology. The database primarily reports the topology of the complete protein chain. More detailed information about subchain topologies can be obtained by calculating a knot map, which records the topology of different portions of the sequence. Because producing full knot maps for hundreds of thousands of structures would require substantial computational resources, these calculations are performed on demand rather than precomputed for the entire AlphaFold DB v4 dataset.
Radiation Source Use and Replacement: Abbreviated Version. National Academies Press. ISBN 978-0-309-11014-3. O'Neil, Marydale J.; Heckelman, Patricia E.; Roman, Cherie B., eds. (2006). The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (14th ed.). Merck Research Laboratories, Merck & Co. ISBN 978-0-911910-00-1. Osborne-Lee, I. W.; Alexander, C. W. (1995). "Californium-252: A Remarkable Versatile Radioisotope". Oak Ridge Technical Report ORNL/TM-12706. doi:10.2172/205871. OSTI 205871. Ruiz-Lapuente, P.; Canal, R.; Isern, J. (1996). Thermonuclear Supernovae. Springer Science+Business Media. ISBN 978-0-7923-4359-2. Seaborg, Glenn T.; Loveland, Walter D. (1990). The Elements Beyond Uranium. John Wiley & Sons, Inc. ISBN 978-0-471-89062-1. Seaborg, Glenn T. (1994). Modern alchemy: selected papers of Glenn T. Seaborg. World Scientific. ISBN 978-981-02-1440-1. Seaborg, Glenn T. (1996). Adloff, J. P. (ed.). One Hundred Years after the Discovery of Radioactivity. Oldenbourg Wissenschaftsverlag. ISBN 978-3-486-64252-0. Seaborg, Glenn T. (2004). "Californium". In Geller, Elizabeth (ed.). Concise Encyclopedia of Chemistry. McGraw-Hill. p. 94. ISBN 978-0-07-143953-4. Szwacki, Nevill Gonzalez; Szwacka, Teresa (2010). Basic Elements of Crystallography. Pan Stanford. ISBN 978-981-4241-59-5. Walker, Perrin; Tarn, William H., eds. (1991). Handbook of Metal Etchants. CRC Press. ISBN 978-0-8493-3623-2. Weeks, Mary Elvira; Leichester, Henry M. (1968). "21: Modern Alchemy". Discovery of the Elements. Journal of Chemical Education. pp. 848–850. ISBN 978-0-7661-3872-8.
== Mechanism == The nuclear force holding an atomic nucleus together is very strong, in general much stronger than the repulsive electromagnetic forces between the protons. However, the nuclear force is also short-range, dropping quickly in strength beyond about 3 femtometers, while the electromagnetic force has an unlimited range. The strength of the attractive nuclear force keeping a nucleus together is thus proportional to the number of the nucleons, but the total disruptive electromagnetic force of proton-proton repulsion trying to break the nucleus apart is roughly proportional to the square of its atomic number. A nucleus with 210 or more nucleons is so large that the strong nuclear force holding it together can just barely counterbalance the electromagnetic repulsion between the protons it contains. Alpha decay occurs in such nuclei as a means of increasing stability by reducing size. One curiosity is why alpha particles, helium nuclei, should be preferentially emitted as opposed to other particles like a single proton or neutron or other atomic nuclei. Part of the reason is the high binding energy of the alpha particle, which means that its mass is less than the sum of the masses of two free protons and two free neutrons. This increases the disintegration energy.
Sources: en.wikipedia.org
Bitcoin wallets were the first cryptocurrency wallets, enabling users to store the information necessary to transact bitcoins. The first wallet program, simply named Bitcoin, and sometimes referred to as the Satoshi client, was released in 2009 by Nakamoto as open-source software. Bitcoin Core is among the best known clients. Forks of Bitcoin Core exist such as Bitcoin Unlimited. Wallets can be full clients, with a full copy of the blockchain to check the validity of mined blocks, or lightweight clients, just to send and receive transactions without a local copy of the entire blockchain. Third-party internet services, called online wallets or hot wallets, store users' credentials on their servers, making them susceptible of hacks. Cold storage protects bitcoins from such hacks by keeping private keys offline, either through specialized hardware wallets or paper printouts.
=== Vocalizations === The American kestrel has three basic vocalizations – the "klee" or "killy", the "whine", and the "chitter". The "klee" is usually delivered as a rapid series – klee, klee, klee, klee when the kestrel is upset or excited. This call is used in a wide variety of situations and is heard from both sexes, but the larger females typically have lower-pitched voices than the males. The "whine" call is primarily associated with feeding but is also uttered during copulation. The "chitter" is used in activities that involve interaction between male and female birds, including courtship feeding, copulation, and the feeding of nestlings. Nestlings can produce calls similar to those of adults at 16 days old.
On 22 January 2020, Valve employee David Feise stated in a Reddit AMA that Mike Morasky, the sole composer of the then-upcoming Half-Life: Alyx, had consulted Bailey about his approach to the music of the Half-Life series and would likely honor his advice when composing the music for Alyx.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.